<PAGE> 1
PROSPECTUS SUPPLEMENT NO. 6 Filed Pursuant to Rule 424(b)(3)
(to Prospectus dated April 3, 2000) Registration No. 333-33252
HUMAN GENOME SCIENCES, INC.
--------------------
$225,000,000
5% Convertible Subordinated Notes Due 2007
and
2,000,000 Shares of Common Stock
Issuable Upon Conversion of the Notes
--------------------
The following information supplements information contained in our
prospectus dated April 3, 2000, relating to the potential offer and sale
from time to time by holders of the notes and the underlying shares of
our common stock. See "Plan of Distribution" in our prospectus.
This prospectus supplement may only be delivered or used in
connection with our prospectus. This prospectus supplement is
incorporated by reference into our prospectus. Our common stock is listed
on The Nasdaq National Market under the symbol "HGSI."
NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION HAS APPROVED
OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS
SUPPLEMENT OR THE PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION
TO THE CONTRARY IS A CRIMINAL OFFENSE.
Prospectus Supplement dated June 7, 2000
<PAGE> 2
The notes were originally issued by us and sold by Credit Suisse
First Boston Corporation, as initial purchaser, in a transaction exempt
from the registration requirements of the Securities Act to persons
reasonably believed by the initial purchaser to be qualified
institutional buyers or other institutional accredited investors. Selling
holders, including their transferees, pledgees or donees or their
successors, may from time to time offer and sell any or all of the notes
and common stock into which the notes are convertible.
--------------------
The following table supplements the information in our prospectus
with respect to the selling holders and the principal amounts of notes
and common stock they beneficially own that may be offered under our
prospectus. The information is based on information provided by or on
behalf of the selling holders. All information provided in this
prospectus supplement is as of June 6, 2000.
The selling holders may offer all, some or none of the notes or
common stock into which the notes are convertible. Thus, we cannot
estimate the amount of the notes or the common stock that will be held by
the selling holders upon termination of any sales. The column showing
ownership after completion of the offering assumes that the selling
holders will sell all of the securities offered by this prospectus
supplement. In addition, the selling holders identified below may have
sold, transferred or otherwise disposed of all or a portion of their
notes since the date on which they provided the information about their
notes in transactions exempt from the registration requirements of the
Securities Act. None of the selling holders has had any material
relationship with us or our affiliates within the past three years,
except that Credit Suisse First Boston Corporation acted as the initial
purchaser in connection with our 5 1/2% Convertible Subordinated Notes
Due 2006, 5% Convertible Subordinated Notes Due 2006, 5% Convertible
Subordinated Notes Due 2007, and our 3 3/4% Convertible Subordinated
Notes Due 2007 and acted as the dealer manager in connection with the
offer we made to holders of our 5 1/2% Convertible Subordinated Notes Due
2006. No selling holder named in the table below beneficially owns one
percent or more of our common stock. Common stock owned prior to the
offering and after completion of the offering includes shares of common
stock issuable upon conversion of our 5 1/2% Convertible Subordinated
Notes Due 2006 and 3 3/4% Convertible Subordinated Notes Due 2007.
<TABLE>
<CAPTION>
COMMON
STOCK OWNED
PRINCIPAL AMOUNT OF COMMON STOCK COMMON AFTER
NOTES BENEFICIALLY OWNED PRIOR TO STOCK COMPLETION OF
NAME OWNED AND OFFERED THE OFFERING OFFERED THE OFFERING
---- ----------------- -------------- ------- -------------
<S> <C> <C> <C> <C>
Credit Suisse First Boston Corporation ........... $1,150,000 10,222 10,222 --
</TABLE>
Information concerning the selling holders may change from time to
time and any changed information will be set forth in future prospectus
supplements if and when necessary. Further, the per share conversion
price, and therefore the number of shares of common stock issuable upon
conversion of the notes, is subject to adjustment. As a result, the
number of shares of common stock into which the notes are convertible may
increase or decrease.
S - 2
